Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | F2R | P25116 | 11/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | PTPRC | P08575 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8880595 | 0.91 | KDM4E (0.60) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL10780717 | 0.88 | LMNA (0.57) | NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7452128 | 0.88 | LMNA (0.57) | NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2702562 | 0.87 | RAB9A (0.63) | NPC1RAB9ASMN1; SMN2F2RALDH1A1 | |
| SCHEMBL4599065 | 0.86 | LMNA (0.63) | NPC1HTTRAB9ASMN1; SMN2F2R | |
| SCHEMBL10975643 | 0.85 | F2R (0.73) | RAB9AF2RMTNR1BALDH1A1MAPT | |
| SCHEMBL6561208 | 0.84 | RAB9A (0.50) | HTTRAB9AMTNR1BALDH1A1MAPT | |
| SCHEMBL5199244 | 0.81 | LMNA (0.49) | RAB9ASMN1; SMN2ALDH1A1MAPTMAPK1 | |
| SCHEMBL5199253 | 0.81 | LMNA (0.49) | RAB9ASMN1; SMN2ALDH1A1MAPTMAPK1 | |
| SCHEMBL11756097 | 0.80 | POLB (0.72) | RAB9ASMN1; SMN2F2RMTNR1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445516-B2 | Pharmaceutical composition for promoting angiogenesis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-05-21 | — | — | US | disclosed |
| US-20090187025-A1 | Pharmaceutical composition for promoting angiogenesis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-1708705-B1 | USE OF PIPERIDINE DERIVATIVES FOR PROMOTING ANGIOGENESIS | OTSUKA PHARMA CO LTD (JP) | 2009-02-18 | — | — | EP | disclosed |
| EP-1708705-A1 | PHARMACEUTICAL COMPOSITION FOR PROMOTING ANGIOGENESIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005072734-A1 | PHARMACEUTICAL COMPOSITION FOR PROMOTING ANGIOGENESIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090187025-A1 | Pharmaceutical composition for promoting angiogenesis | FLT1, FLT4, KDR | NPC1 2349/4885HTT 3888/4885RAB9A 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.